News

Biomarkers have become essential tools in modern medicine, providing critical insights into disease states, treatment efficacy, and patient management. The development of reliable biomarker assays is crucial for translating biomarker discoveries into clinical practice. This post will discuss the key steps in biomarker assay development and the rigorous validation processes necessary to ensure their reliability and applicability. What is a Biomarker? A biomarker is a measurabl

In the field of immunoassays and in vitro diagnostics (IVD), ensuring the accuracy and reliability of tests is paramount. These diagnostic tools are critical in clinical settings, guiding decisions that impact patient care. However, a common point of confusion arises between the concepts of verification and validation. Though often used interchangeably, they represent distinct processes with specific purposes. This article aims to demystify these terms and elucidate their rol

In vitro diagnostics (IVD) are pivotal tools in healthcare, aiding in disease diagnosis, monitoring, and treatment decisions. However, one of the fundamental challenges in IVD development lies in striking the delicate balance between sensitivity and specificity. Achieving high sensitivity ensures the accurate detection of true positive cases, while maximizing specificity minimizes false positive results. In this article, we delve into the complexities of this dilemma and exp

In the realm of biomedical research and clinical diagnostics, immunoassays play a pivotal role in detecting and quantifying biomolecules with high specificity and sensitivity. From monitoring disease biomarkers to drug development and beyond, the reliability of immunoassay results is paramount. However, achieving consistent and accurate outcomes requires rigorous quality control measures throughout the assay development process. Quality control (QC) in immunoassay development

In the realm of biopharmaceutical development, understanding and mitigating the immunogenicity of therapeutic proteins is crucial for ensuring patient safety and treatment efficacy. Antibody drug assays (ADA assays) play a pivotal role in assessing the immunogenic potential of biotherapeutics by detecting the presence of anti-drug antibodies (ADAs) in patient samples. However, the development of ADA assays presents unique challenges that require careful consideration and str

In the realm of biopharmaceutical development, understanding and mitigating the immunogenicity of therapeutic proteins is paramount. Antibody drug assays (ADA assays) serve as vital tools in assessing immunogenicity by detecting anti-drug antibodies (ADAs) in patient samples. However, selecting the appropriate platform for ADA assays is a critical decision that significantly impacts assay sensitivity, specificity, and reliability. This article explores the various platforms

In the rapidly evolving landscape of life sciences and diagnostics, immunoassays and ELISAs play a pivotal role in detecting and quantifying various biomolecules. Immunoassay design and development demand meticulous attention to detail, specialised knowledge, and cutting-edge technologies. Many organisations are recognizing the benefits of outsourcing these critical processes to dedicated experts. In this article, we explore the compelling reasons why you might want to outso

At Fleet Bioprocessing Ltd., we take pride in being a Gyrolab Certified Assay Transfer and Development Partner. Fleet Bioprocessing Ltd. enjoys global recognition for our proficiency in bioconjugation chemistry. Our dedication to excellence has cemented our reputation as leaders in the field, trusted by clients worldwide. This complemented with our assay design expertise allows us to deliver reproducible and cost-effective critical reagents specifically designed for all your

Optimising an ELISA method involves several steps to enhance the accuracy, sensitivity, specificity, and overall performance of the assay. At Fleet Bioprocessing , we have the expertise in immunoassay development to support your specific project, but here are some points to consider. Antibody and antigen selection : Your assay will only ever be as good as the reagents used. Whilst for a novel target the choice of antibody may be limited, where a range of antibodies are availa